The state of New Jersey is suing a maker of the powerful opioid fentanyl for consumer fraud, charging it with “blatant disregard for the law… flooding the market,” putting hundreds of lives at risk, and for actions that “led to the death of at least one New Jersey resident.”
Introducing the lawsuit yesterday, NJ attorney general Chris Porrino accused the Arizona-based drug manufacturer INSYS Therapeutics of “titanic greed” for the way it marketed Subsys for broad patient use even though the FDA had approved it only for cancer patients in extreme pain.
Porrino said INSYS sold more than $74 million worth of Subsys in New Jersey between 2012 and the third quarter of 2016. “We’re looking to recover money. We’re also looking to send a message,” he said.
Read the full story on NJTV News Online, a content partner of NJ Spotlight.